Beijing’s New Fast-track Review For Innovative Medicines Might Be Open Only To Made-in-China Drugs
This article was originally published in PharmAsia News
BEIJING - China's fast-track review process for certain classes of new drugs, unveiled earlier this month, marks an advance in the country's budding support for innovative medicines, but also might be open only to domestically made products, according to Chinese and American lawyers
You may also be interested in...
SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6